icad inc. (NASDAQ:ICAD) announced its quarterly earnings data on Tuesday, August 8th. The technology company reported ($0.16) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.03, Bloomberg Earnings reports. icad inc. had a negative return on equity of 44.39% and a negative net margin of 34.74%. The company had revenue of $6.41 million during the quarter, compared to the consensus estimate of $6.41 million.
icad inc. (ICAD) opened at 3.65 on Friday. The company’s market cap is $60.57 million. icad inc. has a 52-week low of $2.82 and a 52-week high of $6.49. The company’s 50 day moving average price is $3.92 and its 200 day moving average price is $4.35.
Separately, Laidlaw reiterated a “buy” rating and issued a $11.00 price objective on shares of icad inc. in a research report on Tuesday, July 25th.
TRADEMARK VIOLATION NOTICE: “icad inc. (ICAD) Issues Quarterly Earnings Results” was originally published by BNB Daily and is the sole property of of BNB Daily. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/icad-inc-icad-posts-earnings-results-beats-expectations-by-0-03-eps-updated.html.
Several hedge funds have recently bought and sold shares of ICAD. Argent Capital Management LLC increased its stake in icad inc. by 13.2% in the second quarter. Argent Capital Management LLC now owns 713,650 shares of the technology company’s stock worth $2,990,000 after buying an additional 82,967 shares in the last quarter. Vanguard Group Inc. increased its stake in icad inc. by 0.4% in the second quarter. Vanguard Group Inc. now owns 456,377 shares of the technology company’s stock worth $1,912,000 after buying an additional 2,007 shares in the last quarter. Finally, Essex Investment Management Co. LLC increased its stake in icad inc. by 822.3% in the second quarter. Essex Investment Management Co. LLC now owns 139,766 shares of the technology company’s stock worth $586,000 after buying an additional 124,612 shares in the last quarter. 25.16% of the stock is owned by institutional investors.
About icad inc.
iCAD, Inc is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy).
Receive News & Ratings for icad inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for icad inc. and related companies with MarketBeat.com's FREE daily email newsletter.